AbbVie Cash Flow Statement
ABBV / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
AbbVie generated $19.0B in operating cash flow and $17.8B in free cash flow in FY2025. Free cash flow margin was 29.1% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $4.2B | $4.3B | $4.9B | $11.8B | $11.5B | $4.6B | $7.9B | $5.7B | $5.3B | $6.0B | $5.1B | $1.8B | - | - | - |
| Depreciation & Amortization | - | - | - | - | - | - | - | - | - | - | - | - | - | $525.0M | $508.0M |
| Operating Cash Flow | $19.0B | $18.8B | $22.8B | $24.9B | $22.8B | $17.6B | $13.3B | $13.4B | $10.0B | $7.0B | $7.5B | $3.5B | $6.3B | $6.3B | $6.2B |
| Capital Expenditures | $1.2B | $974.0M | $777.0M | $695.0M | $787.0M | $798.0M | $552.0M | $638.0M | $529.0M | $479.0M | $532.0M | $612.0M | $491.0M | $333.0M | $356.0M |
| Free Cash Flow | $17.8B | $17.8B | $22.1B | $24.2B | $22.0B | $16.8B | $12.8B | $12.8B | $9.4B | $6.6B | $7.0B | $2.9B | $5.8B | $6.0B | $5.9B |
| Share Buybacks | $980.0M | $1.7B | $2.0B | $1.5B | $934.0M | $978.0M | $629.0M | $12.0B | $1.4B | $6.0B | $7.6B | $665.0M | $320.0M | - | - |
| Dividends Paid | $11.7B | $11.0B | $10.5B | $10.0B | $9.3B | $7.7B | $6.4B | $5.6B | $4.1B | $3.7B | $3.3B | $2.7B | $2.6B | - | - |
| FCF Margin | 29.1% | 31.6% | 40.6% | 41.8% | 39.1% | 36.7% | 38.4% | 39.1% | 33.4% | 25.6% | 30.6% | 14.7% | 30.7% | 32.7% | 33.8% |